Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07720843 | TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)(TaBleMM) | not yet recruiting | Phase 1 | 50 | Montefiore Medical CenterOTHER | 0 | Jul 22, 2026 | clinicaltrials |
| NCT07713459 | A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | not yet recruiting | Phase 2 | 105 | Kure Cells, INCINDUSTRY | 0 | Jul 20, 2026 |
| clinicaltrials |
| NCT07713511 | INfections in Patients Treated With CAR-T(IN-CART) | not yet recruiting | — | 290 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07714187 | A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides | not yet recruiting | Phase 1 | 30 | SecuraBioINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07714421 | Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients | not yet recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07709884 | A Single-center, Prospective, Single-arm Clinical Study Exploring the Treatment of Newly Diagnosed Multiple Myeloma Patients With t(11;14) Suitable for Transplantation Using the SonKRd Regimen | not yet recruiting | Phase 4 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07710131 | Neurocognitive Assessment CNSL and LGG | not yet recruiting | N/A | 36 | Dana-Farber Cancer InstituteOTHER | 0 | Jul 17, 2026 | clinicaltrials |
| NCT07711327 | Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy | not yet recruiting | — | 500 | Tina BaykanerOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07711483 | GLORY: Glofit-GemOx With Liso-Cel For Lymphoma(GLORY) | not yet recruiting | Phase 2 | 56 | Massachusetts General HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04871477 | Adoption of Audio Recording in the Outpatient Supportive Care Center | not yet recruiting | — | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07706959 | New Genotype-guided Treatment in Newly Diagnosed PTCL(G08) | not yet recruiting | Phase 1 / Phase 2 | 108 | Ruijin HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07164469 | Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma | not yet recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705308 | A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma | not yet recruiting | Phase 2 | 140 | Ruijin HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07698080 | Dexamethasone, Intravenous Injection of Human Immunoglobulin, and Increased Infusion of Mononuclear Cells to Reduce Donor Specific Antibodies in Haploidentical Hematopoietic Stem Cell Transplantation | not yet recruiting | Phase 2 | 60 | Hematology department of the 920th hospitalOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07702851 | A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP | not yet recruiting | Phase 2 | 47 | Yonsei UniversityOTHER | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07703644 | Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients(CZA-TDM) | not yet recruiting | — | 60 | Sizhou FengOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07254793 | Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT | not yet recruiting | Phase 1 | 94 | University of ArizonaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07599423 | A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 96 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment | not yet recruiting | Phase 2 | 138 | SWOG Cancer Research NetworkNETWORK | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07697339 | HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma | not yet recruiting | Phase 1 | 40 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jul 13, 2026 | clinicaltrials |
| NCT07695740 | Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma | not yet recruiting | Phase 2 | 64 | Excyte Biopharma LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07695896 | Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | not yet recruiting | — | 200 | Yanyan LiuOTHER_GOV | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07696169 | Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers | not yet recruiting | — | 1,000 | Shenzhen Third People's HospitalOTHER | 0 | Jul 10, 2026 | clinicaltrials |
| NCT07696481 | Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia(R/R AL) | not yet recruiting | Early Phase 1 | 18 | Zhujiang HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07691450 | Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma | not yet recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06050850 | Healthy Weight Intervention Families During ALL Treatment: NOURISH-ALL(NOURISH-ALL) | not yet recruiting | N/A | 20 | University of Kansas Medical CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07420959 | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia | not yet recruiting | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07572123 | Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 374 | National Cancer Institute (NCI)NIH | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07690891 | Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia | not yet recruiting | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07691008 | Wearable Data for Personalized Prognostication in Cancer: A Registry Protocol | not yet recruiting | — | 1,200 | City of Hope Medical CenterOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07691034 | Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry | not yet recruiting | — | 40 | Odense University HospitalOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT07686965 | Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse | not yet recruiting | Phase 3 | 191 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07687004 | Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification(AL-005) | not yet recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07682792 | Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia(GEMSTONE) | not yet recruiting | Phase 2 | 24 | Washington University School of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07684274 | Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics | not yet recruiting | — | 290 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Jul 6, 2026 | clinicaltrials |
| NCT07684950 | Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy | not yet recruiting | Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06739447 | Hospital Based Continuous Patient Monitoring System | not yet recruiting | N/A | 250 | University of Alabama at BirminghamOTHER | 0 | Jul 2, 2026 | clinicaltrials |
| NCT07682415 | Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL:Stop Trial 2.0(ZS) | not yet recruiting | Phase 2 | 60 | Yi ShuhuaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07557056 | Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | not yet recruiting | Phase 2 | 25 | Jennifer WoyachOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07677813 | Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma | not yet recruiting | Phase 2 | 66 | Ou Bai, MD/PHDOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678307 | A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07679919 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies | not yet recruiting | Phase 1 | 27 | Luminary TherapeuticsINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07597941 | Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients | not yet recruiting | Phase 2 / Phase 3 | 20 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 0 | Jun 30, 2026 | clinicaltrials |
| NCT07674810 | A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia | not yet recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07676175 | A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL) | not yet recruiting | Phase 2 | 120 | BeBetter Med IncINDUSTRY | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07676877 | Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma | not yet recruiting | Phase 1 | 18 | Nathan DenlingerOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07528417 | Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)(MYELO-CAN:ABX) | not yet recruiting | Phase 2 | 75 | University of ManitobaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07672964 | CD45RA-depleted DLI for the Prevention of Viral Infections in High-risk Patients After Haploidentical Transplantation(CD45RADLIPx) | not yet recruiting | Phase 1 | 30 | Ruijin HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07674212 | Take5Care+: A Self-management Educational Intervention(Take5Care+) | not yet recruiting | N/A | 20 | Jitka VseteckovaOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07670260 | GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma | not yet recruiting | Early Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 22, 2026source: clinicaltrials